Saudi Embassy in Paris clarifies that what was reported in media about arrest of Saudi citizen suspected in the case of citizen Jamal Khashoggi is incorrect, calls for his immediate release    Winners of "Tuwaiq International Sculpture Symposium 2021" Announced    Jordan Records 6,392 New Cases of COVID-19    Aramco and Larsen & Toubro to Collaborate on Manufacturing Sector Development    KSrelief Launches Food Security Project in Ma'rib, Yemen    Saudi Stock Exchange Main Index Ends Trading Higher at 11,108.20 Points    OIC Strongly Condemns Houthi's Launch of Ballistic Missiles towards Riyadh and Khamis Mushait    Custodian of the Two Holy Mosques Chairs Cabinet's Virtual Session    Egypt Condemns Houthi Militia's Targeting of Riyadh with a Ballistic Missile    Saudi Press: Saudi Arabia Always Seeks to Enhance its Relations With GCC Countries in Various Fields    Bahrain strongly condemns launch of ballistic missile by terrorist Houthi militia towards Riyadh city    Saudi Aramco Announces $15.5 Billion Landmark Gas Pipeline Deal with Global Consortium    UN deplores conviction and sentencing of Aung San Suu Kyi    Dr. Al Rabeeah inaugurates launch of first 154 aid trucks to Yemen    Crown Prince embarks on Gulf states tour    SWCC shares initiatives in realizing Saudi Green goals in London Forum    King Abdullah Port sponsors SMME reinforcing commitment to maritime sector    Saudi Export Development Authority Organizes Saudi Trade Mission to USA    Coalition forces shoot down two Houthi-fired drones    Saudi Arabia's new COVID-19 cases continue its slight rise    Saudi and GCC entrants set to dominate motorcycle and quad battles in Hail    LuLu group and EFAA group make kindness and support priority on World Disability Day.    10 days to go until Riyadh comes alive with MDLBEAST'S majestic shows    World Directs Attention to Final Round of FIA Cross Country Rally World Cup in Hail    Saudi ministry stresses need for wearing masks, social distancing in mosques    Pakistani education minister lauds Saudi e-learning success during the pandemic    Next pandemic could be more lethal than Covid, says vaccine creator    5-day Jeddah international motor show starts Today at 6 PM    Lewis Hamilton wins thrilling Saudi Arabian Grand Prix    Crown Prince attends inaugural Saudi Arabian Grand Prix    Deputy Governor of Hail: Hail International Rally is a practical translation of the wise leadership's support    Hail International Rally to Kick off Tomorrow    Hamilton sets pace in free trials in Formula 1 STC Saudi Arabian Grand Prix    Red Sea Immersive to provide enthralling experience: Liz Rosenthal    Invest in Saudi Arabia Initiative Announces its Partnership with Formula 1 Saudi Grand Prix    Duchess of Sussex wins latest court battle with Mail on Sunday publisher    Trolls join UN campaign for healthier eating, sustainable living    BIENALSUR Exhibition Arrives in Jeddah at Historic Site of Qasr Khuzam    Saudi Hind Al-Showaier Elected Regional Director of World Federation of the Deaf    Saudi Film Commission launch its strategy to develop film and cinema sector    Bollywood superstar Salman Khan to dazzle Riyadh Season on Dec. 10    Bollywood star's 'India got freedom in 2014' remark stirs controversy    23 Saudi women obtain favorable verdicts in 'adhl' lawsuits    Bride's fingerprint not required in revised e-marriage contract    Pilgrims Perform Dhuhr and Asr Prayers at Arafat Holy Site    Council of Senior Scholars: Muslim Brothers' Group Don't Represent Method of Islam, rather only Follows its Partisan Objectives, Violating our Graceful Religion    Eid Al-Adha Prayer Performed at the Grand Holy Mosque    Pilgrims Perform Dhuhr and Asr Prayers in Arafat Holy Site    

Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.

EU publishes AstraZeneca contract amid coronavirus vaccine row
Published in The Saudi Gazette on 29 - 01 - 2021

The European Union published its coronavirus vaccine contract with AstraZeneca amid an ongoing row over delays to vaccine deliveries.
It came after European Commission President Ursula von der Leyen weighed in on the dispute with the pharmaceutical company, telling a German radio station on Friday that there is "no plausible explanation" for its delay in supplying its vaccine to the EU.
The European Medicines Agency is expected on Friday to authorize the use of the vaccine AstraZeneca developed with Oxford University. It would be the third cleared for use in the EU, after the BioNTech-Pfizer and Moderna vaccines.
The European Commission has been locked in a dispute with the British-Swedish pharmaceutical company since it said it would deliver far smaller than expected supplies to EU member nations.
The European Union is looking at legal ways to guarantee the delivery of all the COVID-19 vaccine doses it bought from AstraZeneca and other drugmakers.
The Commission President increased the pressure on AstraZeneca in her interview, reiterating the EU's view that the contract is unambiguous and its rejection of the company's reasons for cutting planned supplies by at least 60 percent.
"There are binding orders and the contract is crystal clear," she said.
Von der Leyen dismissed the claims by AstraZeneca — which has blamed "glitches" in production — that under its contract with the EU it was only obliged to make "best efforts" to deliver supplies.
"(The phrase) 'best efforts' meant as long as it was not clear whether they (AstraZeneca) can develop a vaccine. We have now passed that time. The vaccine is here."
She added that the Commission wanted to make the contract public. Later, the Commission did just that.
"We want to publish it today," she said. "This is business sensitive data, that's clear. But basically: we want to create transparency on these issues that I have just touched on. We know exactly what is in the contract, which is why it is important to us that it is now made public."
In a sign of the level of EU mistrust in AstraZeneca, on Thursday Belgian authorities inspected a factory in Belgium that is part of AstraZeneca's vaccine production chain. It followed a crisis meeting the previous evening between EU officials and the company which failed to resolve the issue.
Meanwhile, both AstraZeneca and the UK, which has already been using the vaccine, insist it is efficient in older adults. This follows doubt cast in Germany by the country's vaccination commission which declined to recommend its immediate use for people over 65.
EU to 'explore all options'
In a reply to a letter he received from four European government leaders, EU Council President Charles Michel said the EU "should explore all options and make use of all legal means and enforcement measures at our disposal," if negotiations with drug companies don't yield satisfaction.
AstraZeneca said last week that it planned to cut initial deliveries in the EU from the scheduled 80 million doses for the first quarter of the year to 31 million doses. The company cited reduced yields from its manufacturing plants in Europe, but the EU suspects doses produced in Europe have been directed elsewhere.
Michel said the use of the EU treaties would allow the EU and member states to take "appropriate urgent measures, to ensure effective vaccine production and supply for our population".
The European Commission also plans to new rules strengthening the control of vaccine exports to ensure the doses it bought are delivered to the bloc's residents.
The dispute highlights the tension over vaccine supplies as Europe struggles to roll out inoculation programs against the coronavirus.
AstraZeneca and UK refute German claims
The UK and AstraZeneca hit back on Thursday at the draft recommendation in Germany to restrict the use of the vaccine only to people aged 18-64 for now. The country's vaccination advisory committee cited what it said was insufficient data to judge its effectiveness for older people.
"Our own authorities have made it very clear that they think the Oxford AstraZeneca vaccine is very good and efficacious," said British Prime Minister Boris Johnson. "The evidence that they've seen, that they've supplied, is that they think that it is effective across all age groups and provides a good immune response across all age groups."
"The latest analyses of clinical trial data for the AstraZeneca/Oxford COVID-19 vaccine support efficacy in the over 65 years age group. We await a regulatory decision on the vaccine by the EMA in the coming days," an AstraZeneca spokesperson said.
Germany's health minister has stressed that a final decision will not be made until after Friday's EMA meeting. — Euronews

Clic here to read the story from its source.